BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 2019;18:707-29. [PMID: 31324874 DOI: 10.1038/s41573-019-0031-6] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 33.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu C, Miao J, Li M, Zheng Q, Xu F, Pan Y, Wang Y, Yang Z, Xia X, Zhu H, Chen J, Bao S. Characterization of the Estrogen Response Helps to Predict Prognosis and Identify Potential Therapeutic Targets in Cholangiocarcinoma. Front Oncol 2022;12:870840. [DOI: 10.3389/fonc.2022.870840] [Reference Citation Analysis]
2 Pedersen H, Jensen RK, Hansen AG, Gadeberg TAF, Thiel S, Laursen NS, Andersen GR. A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system. J Biol Chem 2020;295:8746-58. [PMID: 32376685 DOI: 10.1074/jbc.RA119.012339] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 Boudhabhay I, Poillerat V, Grunenwald A, Torset C, Leon J, Daugan MV, Lucibello F, El Karoui K, Ydee A, Chauvet S, Girardie P, Sacks S, Farrar CA, Garred P, Berthaud R, Le Quintrec M, Rabant M, de Lonlay P, Rambaud C, Gnemmi V, Fremeaux-Bacchi V, Frimat M, Roumenina LT. Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. Kidney Int 2021;99:581-97. [PMID: 33137339 DOI: 10.1016/j.kint.2020.09.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
4 Elashiry M, Morandini AC, Cornelius Timothius CJ, Ghaly M, Cutler CW. Selective Antimicrobial Therapies for Periodontitis: Win the "Battle and the War". Int J Mol Sci 2021;22:6459. [PMID: 34208697 DOI: 10.3390/ijms22126459] [Reference Citation Analysis]
5 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Blasco M, Guillén E, Quintana LF, Garcia-Herrera A, Piñeiro G, Poch E, Carreras E, Campistol JM, Diaz-Ricart M, Palomo M. Thrombotic microangiopathies assessment: mind the complement. Clin Kidney J 2021;14:1055-66. [PMID: 33841853 DOI: 10.1093/ckj/sfaa195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gregersen E, Betzer C, Kim WS, Kovacs G, Reimer L, Halliday GM, Thiel S, Jensen PH. Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity. J Neuroinflammation 2021;18:177. [PMID: 34399786 DOI: 10.1186/s12974-021-02225-9] [Reference Citation Analysis]
8 Koopman JJE, van Essen MF, Rennke HG, de Vries APJ, van Kooten C. Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys. Front Immunol 2020;11:599974. [PMID: 33643288 DOI: 10.3389/fimmu.2020.599974] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Roe K. Potential New Treatments for Kawasaki Disease, Its Variations, and Multisystem Inflammatory Syndrome. SN Compr Clin Med 2021;:1-5. [PMID: 33786417 DOI: 10.1007/s42399-021-00872-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kisserli A, Schneider N, Audonnet S, Tabary T, Goury A, Cousson J, Mahmoudi R, Bani-Sadr F, Kanagaratnam L, Jolly D, Cohen JH. Acquired decrease of the C3b/C4b receptor (CR1, CD35) and increased C4d deposits on erythrocytes from ICU COVID-19 patients. Immunobiology 2021;226:152093. [PMID: 34022670 DOI: 10.1016/j.imbio.2021.152093] [Reference Citation Analysis]
11 Kumar V. Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. Int Immunopharmacol 2020;88:106980. [PMID: 33182073 DOI: 10.1016/j.intimp.2020.106980] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
12 Delanghe JR, De Buyzere ML, Speeckaert MM. Genetic Polymorphisms in the Host and COVID-19 Infection. Adv Exp Med Biol 2021;1318:109-18. [PMID: 33973175 DOI: 10.1007/978-3-030-63761-3_7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wendt R, Siwy J, He T, Latosinska A, Wiech T, Zipfel PF, Tserga A, Vlahou A, Rupprecht H, Catanese L, Mischak H, Beige J. Molecular Mapping of Urinary Complement Peptides in Kidney Diseases. Proteomes 2021;9:49. [DOI: 10.3390/proteomes9040049] [Reference Citation Analysis]
14 Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD. 'Stealth' corporate innovation: an emerging threat for therapeutic drug development. Nat Immunol 2019;20:1409-13. [PMID: 31562490 DOI: 10.1038/s41590-019-0503-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mastellos DC, Pires da Silva BGP, Fonseca BAL, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol 2020;220:108598. [PMID: 32961333 DOI: 10.1016/j.clim.2020.108598] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 34.0] [Reference Citation Analysis]
16 Chauhan AJ, Wiffen LJ, Brown TP. COVID-19: A collision of complement, coagulation and inflammatory pathways. J Thromb Haemost 2020;18:2110-7. [PMID: 32608159 DOI: 10.1111/jth.14981] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 22.0] [Reference Citation Analysis]
17 Mackman N, Antoniak S, Wolberg AS, Kasthuri R, Key NS. Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. Arterioscler Thromb Vasc Biol 2020;40:2033-44. [PMID: 32657623 DOI: 10.1161/ATVBAHA.120.314514] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 23.5] [Reference Citation Analysis]
18 Armento A, Ueffing M, Clark SJ. The complement system in age-related macular degeneration. Cell Mol Life Sci 2021;78:4487-505. [PMID: 33751148 DOI: 10.1007/s00018-021-03796-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
19 Achazi K, Haag R, Ballauff M, Dernedde J, Kizhakkedathu JN, Maysinger D, Multhaup G. Wechselwirkung von Polyelektrolyt‐Architekturen mit Proteinen und Biosystemen. Angew Chem 2021;133:3926-50. [DOI: 10.1002/ange.202006457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Das A, Rana S. The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19. Comput Biol Chem 2021;92:107482. [PMID: 33845430 DOI: 10.1016/j.compbiolchem.2021.107482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Thurman JM, Laskowski J, Nemenoff RA. Complement and Cancer-A Dysfunctional Relationship? Antibodies (Basel) 2020;9:E61. [PMID: 33167384 DOI: 10.3390/antib9040061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 He S, Gao F, Ma J, Ma H, Dong G, Sheng C. Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer. Angew Chem Int Ed Engl 2021. [PMID: 34240523 DOI: 10.1002/anie.202107347] [Reference Citation Analysis]
23 Hevey R, Pouw RB, Harris C, Ricklin D. Sweet turning bitter: Carbohydrate sensing of complement in host defence and disease. Br J Pharmacol 2021;178:2802-22. [PMID: 33140840 DOI: 10.1111/bph.15307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Tzoumas N, Hallam D, Harris CL, Lako M, Kavanagh D, Steel DHW. Revisiting the role of factor H in age-related macular degeneration: Insights from complement-mediated renal disease and rare genetic variants. Surv Ophthalmol 2021;66:378-401. [PMID: 33157112 DOI: 10.1016/j.survophthal.2020.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Thurman JM. Complement and the Kidney: An Overview. Adv Chronic Kidney Dis 2020;27:86-94. [PMID: 32553250 DOI: 10.1053/j.ackd.2019.10.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
26 Gomez-Arboledas A, Acharya MM, Tenner AJ. The Role of Complement in Synaptic Pruning and Neurodegeneration. Immunotargets Ther 2021;10:373-86. [PMID: 34595138 DOI: 10.2147/ITT.S305420] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol 2021;18:666-82. [PMID: 33958774 DOI: 10.1038/s41569-021-00552-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
28 Briani C, Visentin A. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies. Neurotherapeutics 2022. [PMID: 35349079 DOI: 10.1007/s13311-022-01222-x] [Reference Citation Analysis]
29 Zewde NT. Multiscale Solutions to Quantitative Systems Biology Models. Front Mol Biosci 2019;6:119. [PMID: 31737643 DOI: 10.3389/fmolb.2019.00119] [Reference Citation Analysis]
30 Gavriilaki E, Sakellari I, Gavriilaki M, Anagnostopoulos A. Thrombocytopenia in COVID-19: pathophysiology matters. Ann Hematol 2021;100:2139-40. [PMID: 32683455 DOI: 10.1007/s00277-020-04183-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Van de Walle I, Silence K, Budding K, Van de Ven L, Dijkxhoorn K, de Zeeuw E, Yildiz C, Gabriels S, Percier JM, Wildemann J, Meeldijk J, Simons PJ, Boon L, Cox L, Holgate R, Urbanus R, Otten HG, Leusen JHW, Blanchetot C, de Haard H, Hack CE, Boross P. ARGX-117, a therapeutic complement inhibiting antibody targeting C2. J Allergy Clin Immunol 2021;147:1420-1429.e7. [PMID: 32926878 DOI: 10.1016/j.jaci.2020.08.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
32 Mehata AK, Viswanadh MK, Priya V, Vikas, Muthu MS. Harnessing immunological targets for COVID-19 immunotherapy. Future Virol 2021. [PMID: 34447458 DOI: 10.2217/fvl-2021-0048] [Reference Citation Analysis]
33 de Nooijer AH, Grondman I, Janssen NAF, Netea MG, Willems L, van de Veerdonk FL, Giamarellos-Bourboulis EJ, Toonen EJM, Joosten LAB; RCI-COVID-19 study group. Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes. J Infect Dis 2021;223:214-24. [PMID: 33038254 DOI: 10.1093/infdis/jiaa646] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
34 Eriksson O, Hultström M, Persson B, Lipcsey M, Ekdahl KN, Nilsson B, Frithiof R. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thromb Haemost 2020;120:1720-4. [PMID: 32871607 DOI: 10.1055/s-0040-1715835] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
35 Hajishengallis G, Hasturk H, Lambris JD; Contributing authors. C3-targeted therapy in periodontal disease: moving closer to the clinic. Trends Immunol 2021;42:856-64. [PMID: 34483038 DOI: 10.1016/j.it.2021.08.001] [Reference Citation Analysis]
36 Stahel PF, Barnum SR. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option. Front Immunol 2020;11:1661. [PMID: 32733489 DOI: 10.3389/fimmu.2020.01661] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
37 Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, Huber-Lang M, Piemontese S, Assanelli A, Garlanda C, Lambris JD, Ciceri F. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020;215:108450. [PMID: 32360516 DOI: 10.1016/j.clim.2020.108450] [Cited by in Crossref: 140] [Cited by in F6Publishing: 137] [Article Influence: 70.0] [Reference Citation Analysis]
38 Xu X, Zhang C, Denton DT, O'Connell D, Drolet DW, Geisbrecht BV. Inhibition of the Complement Alternative Pathway by Chemically Modified DNA Aptamers That Bind with Picomolar Affinity to Factor B. J Immunol 2021;206:861-73. [PMID: 33419768 DOI: 10.4049/jimmunol.2001260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Howard MC, Nauser CL, Farrar CA, Sacks SH. Complement in ischaemia-reperfusion injury and transplantation. Semin Immunopathol 2021;43:789-97. [PMID: 34757496 DOI: 10.1007/s00281-021-00896-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020;98:314-322. [PMID: 32461141 DOI: 10.1016/j.kint.2020.05.013] [Cited by in Crossref: 116] [Cited by in F6Publishing: 110] [Article Influence: 58.0] [Reference Citation Analysis]
41 Cerniauskas E, Kurzawa-Akanbi M, Xie L, Hallam D, Moya-Molina M, White K, Steel D, Doherty M, Whitfield P, Al-Aama J, Armstrong L, Kavanagh D, Lambris JD, Korolchuk VI, Harris C, Lako M. Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function. Stem Cells Transl Med 2020;9:1585-603. [PMID: 32815311 DOI: 10.1002/sctm.20-0211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
42 Martin M, Trattner R, Nilsson SC, Björk A, Zickert A, Blom AM, Gunnarsson I. Plasma C4d Correlates With C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients. Front Immunol 2020;11:582737. [PMID: 33133102 DOI: 10.3389/fimmu.2020.582737] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 Keller CW, Lopez JA, Wendel EM, Ramanathan S, Gross CC, Klotz L, Reindl M, Dale RC, Wiendl H, Rostásy K, Brilot F, Lünemann JD. Reply to "Investigating the Immunopathogenic Mechanisms Underlying MOGAD". Ann Neurol 2021. [PMID: 34862658 DOI: 10.1002/ana.26278] [Reference Citation Analysis]
44 Elolimy AA, Washam C, Byrum S, Chen C, Dawson H, Bowlin AK, Randolph CE, Saraf MK, Yeruva L. Formula Diet Alters the Ileal Metagenome and Transcriptome at Weaning and during the Postweaning Period in a Porcine Model. mSystems 2020;5:e00457-20. [PMID: 32753508 DOI: 10.1128/mSystems.00457-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
45 Fan Y, Wang Y, Yu S, Chang J, Yan Y, Wang Y, Bian Y. Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review. Chin Med 2021;16:67. [PMID: 34321065 DOI: 10.1186/s13020-021-00478-3] [Reference Citation Analysis]
46 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
47 Arthur CM, Chonat S, Fasano R, Yee MEM, Josephson CD, Roback JD, Stowell SR. Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions. Transfus Med Rev 2019;33:217-24. [PMID: 31679762 DOI: 10.1016/j.tmrv.2019.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
48 Li J, Liu B. The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy. Cytokine Growth Factor Rev 2021;58:75-81. [PMID: 33558131 DOI: 10.1016/j.cytogfr.2020.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
49 Ricklin D, Mastellos DC, Lambris JD. Therapeutic targeting of the complement system. Nat Rev Drug Discov 2019. [PMID: 31819218 DOI: 10.1038/s41573-019-0055-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
50 Rehman M, Tauseef I, Aalia B, Shah SH, Junaid M, Haleem KS. Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future. Future Virology 2020;15:471-82. [DOI: 10.2217/fvl-2020-0137] [Cited by in Crossref: 9] [Article Influence: 4.5] [Reference Citation Analysis]
51 Wang X, Sahu KK, Cerny J. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. J Thromb Thrombolysis 2021;51:657-62. [PMID: 33063256 DOI: 10.1007/s11239-020-02297-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
52 Kim BJ, Mastellos DC, Li Y, Dunaief JL, Lambris JD. Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. Prog Retin Eye Res 2021;83:100936. [PMID: 33321207 DOI: 10.1016/j.preteyeres.2020.100936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Sharma S, Bhatnagar R, Gaur D. Complement Evasion Strategies of Human Pathogenic Bacteria. Indian J Microbiol 2020;60:283-96. [PMID: 32655196 DOI: 10.1007/s12088-020-00872-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Mishra R, Behera LM, Rana S. Binding of raloxifene to human complement fragment 5a (hC5a): a perspective on cytokine storm and COVID19. J Biomol Struct Dyn 2020;:1-13. [PMID: 32930050 DOI: 10.1080/07391102.2020.1820381] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Vandendriessche S, Cambier S, Proost P, Marques PE. Complement Receptors and Their Role in Leukocyte Recruitment and Phagocytosis. Front Cell Dev Biol 2021;9:624025. [PMID: 33644062 DOI: 10.3389/fcell.2021.624025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
56 Biewenga M, Farina Sarasqueta A, Tushuizen ME, de Jonge-Muller ESM, van Hoek B, Trouw LA. The role of complement activation in autoimmune liver disease. Autoimmun Rev 2020;19:102534. [PMID: 32234403 DOI: 10.1016/j.autrev.2020.102534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
57 Silva de França F, Villas-Boas IM, Cogliati B, Woodruff TM, Reis EDS, Lambris JD, Tambourgi DV. C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake Naja annulifera. Front Immunol 2021;12:652242. [PMID: 33936074 DOI: 10.3389/fimmu.2021.652242] [Reference Citation Analysis]
58 Chen JY, Galwankar NS, Emch HN, Menon SS, Cortes C, Thurman JM, Merrill SA, Brodsky RA, Ferreira VP. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation. Front Immunol 2020;11:1460. [PMID: 32793201 DOI: 10.3389/fimmu.2020.01460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
59 Posch W, Vosper J, Noureen A, Zaderer V, Witting C, Bertacchi G, Gstir R, Filipek PA, Bonn GK, Huber LA, Bellmann-Weiler R, Lass-Flörl C, Wilflingseder D. C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2-infected primary human airway epithelia. J Allergy Clin Immunol 2021;147:2083-2097.e6. [PMID: 33852936 DOI: 10.1016/j.jaci.2021.03.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
60 Laursen NS, Pedersen DV, Gytz H, Zarantonello A, Bernth Jensen JM, Hansen AG, Thiel S, Andersen GR. Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System. Front Immunol 2020;11:1504. [PMID: 32849513 DOI: 10.3389/fimmu.2020.01504] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Pouw RB, Ricklin D. Tipping the balance: intricate roles of the complement system in disease and therapy. Semin Immunopathol 2021;43:757-71. [PMID: 34698894 DOI: 10.1007/s00281-021-00892-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Lo MW, Woodruff TM. Complement: Bridging the innate and adaptive immune systems in sterile inflammation. J Leukoc Biol 2020;108:339-51. [PMID: 32182389 DOI: 10.1002/JLB.3MIR0220-270R] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
63 Noris M. The case of complement inhibitors. Adv Biol Regul 2021;81:100822. [PMID: 34454870 DOI: 10.1016/j.jbior.2021.100822] [Reference Citation Analysis]
64 Dujardin P, Vandenbroucke RE, Van Hoecke L. Fighting fire with fire: the immune system might be key in our fight against Alzheimer's disease. Drug Discov Today 2022:S1359-6446(22)00004-6. [PMID: 35032668 DOI: 10.1016/j.drudis.2022.01.004] [Reference Citation Analysis]
65 Warwick CA, Keyes AL, Woodruff TM, Usachev YM. The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain. J Biol Chem 2021;297:101085. [PMID: 34411562 DOI: 10.1016/j.jbc.2021.101085] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Chouaki Benmansour N, Carvelli J, Vivier É. [Involvement of the complement cascade in severe forms of COVID-19]. Med Sci (Paris) 2021;37:333-41. [PMID: 33835019 DOI: 10.1051/medsci/2021021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Ahmad A, Mandwie M, Dreismann AK, Smyth CM, Doyle H, Malik TH, Pickering MC, Lachmann PJ, Alexander IE, Logan GJ. Adeno-Associated Virus Vector Gene Delivery Elevates Factor I Levels and Downregulates the Complement Alternative Pathway In Vivo. Hum Gene Ther 2021. [PMID: 34238030 DOI: 10.1089/hum.2021.022] [Reference Citation Analysis]
68 Mastellos DC, Ricklin D, Sfyroera G, Sahu A. From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors. Clin Immunol 2021;:108785. [PMID: 34147650 DOI: 10.1016/j.clim.2021.108785] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
69 Arias-Cabrales C, Rodriguez-Garcia E, Gimeno J, Benito D, Pérez-Sáez MJ, Redondo-Pachón D, Buxeda A, Burballa C, Crespo M, Riera M, Pascual J. Role of C5aR1 and C5L2 Receptors in Ischemia-Reperfusion Injury. J Clin Med 2021;10:974. [PMID: 33801177 DOI: 10.3390/jcm10050974] [Reference Citation Analysis]
70 Caetano R, Cordeiro Dias Villela Correa M, Villardi P, Almeida Rodrigues PH, Garcia Serpa Osorio-de-Castro C. Dynamics of patents, orphan drug designation, licensing, and revenues from drugs for rare diseases: The market expansion of eculizumab. PLoS One 2021;16:e0247853. [PMID: 33667235 DOI: 10.1371/journal.pone.0247853] [Reference Citation Analysis]
71 Jodele S, Köhl J. Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol 2021;178:2832-48. [PMID: 32643798 DOI: 10.1111/bph.15187] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
72 Villas-Boas GR, Rescia VC, Paes MM, Lavorato SN, Magalhães-Filho MF, Cunha MS, Simões RDC, Lacerda RB, Freitas-Júnior RS, Ramos BHDS, Mapeli AM, Henriques MDST, Freitas WR, Lopes LAF, Oliveira LGR, Silva JGD, Silva-Filho SE, Silveira APSD, Leão KV, Matos MMS, Fernandes JS, Cuman RKN, Silva-Comar FMS, Comar JF, Brasileiro LDA, Santos JND, Oesterreich SA. The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents. Molecules 2020;25:E4086. [PMID: 32906733 DOI: 10.3390/molecules25184086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
73 Friščić J, Hoffmann MH. Stromal cell regulation of inflammatory responses. Curr Opin Immunol 2021;74:92-9. [PMID: 34847474 DOI: 10.1016/j.coi.2021.10.006] [Reference Citation Analysis]
74 Bomback AS, Appel GB, Gipson DS, Hladunewich MA, Lafayette R, Nester CM, Parikh SV, Smith RJH, Trachtman H, Heeger PS, Ram S, Rovin BH, Ali S, Arceneaux N, Ashoor I, Bailey-Wickins L, Barratt J, Beck L, Cattran DC, Cravedi P, Erkan E, Fervenza F, Frazer-Abel AA, Fremeaux-Bacchi V, Fuller L, Gbadegesin R, Hogan JJ, Kiryluk K, le Quintrec-Donnette M, Licht C, Mahan JD, Pickering MC, Quigg R, Rheault M, Ronco P, Sarwal MM, Sethna C, Spino C, Stegall M, Vivarelli M, Feldman DL, Thurman JM. Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis 2021:S0272-6386(21)00884-2. [PMID: 34571062 DOI: 10.1053/j.ajkd.2021.07.025] [Reference Citation Analysis]
75 Ispasanie E, Muri L, Schubart A, Thorburn C, Zamurovic N, Holbro T, Kammüller M, Pluschke G. Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals. Front Immunol 2021;12:747594. [PMID: 34691058 DOI: 10.3389/fimmu.2021.747594] [Reference Citation Analysis]
76 Yang S, Li T, Jia H, Gao M, Li Y, Wan X, Huang Z, Li M, Zhai Y, Li X, Yang X, Wang T, Liang J, Gu Q, Luo X, Qian L, Lu S, Liu J, Song Y, Wang F, Sun X, Yu D. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Sci Transl Med 2022;14:eabj2177. [PMID: 35648811 DOI: 10.1126/scitranslmed.abj2177] [Reference Citation Analysis]
77 Chouaki Benmansour N, Carvelli J, Vivier E. Complement cascade in severe forms of COVID-19: Recent advances in therapy. Eur J Immunol 2021;51:1652-9. [PMID: 33738806 DOI: 10.1002/eji.202048959] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
78 Marsh LJ, Kemble S, Reis Nisa P, Singh R, Croft AP. Fibroblast pathology in inflammatory joint disease. Immunol Rev 2021;302:163-83. [PMID: 34096076 DOI: 10.1111/imr.12986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Chan D, Bennett PR, Lee YS, Kundu S, Teoh TG, Adan M, Ahmed S, Brown RG, David AL, Lewis HV, Gimeno-molina B, Norman JE, Stock SJ, Terzidou V, Kropf P, Botto M, Macintyre DA, Sykes L. Microbial-driven preterm labour involves crosstalk between the innate and adaptive immune response. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-28620-1] [Reference Citation Analysis]
80 Kiss MG, Binder CJ. The multifaceted impact of complement on atherosclerosis. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.03.014] [Reference Citation Analysis]
81 Li L, Cong B, Yu X, Deng S, Liu M, Wang Y, Wang W, Gao M, Xu Y. The expression of membrane-bound complement regulatory proteins CD46, CD55 and CD59 in oral lichen planus. Arch Oral Biol 2021;124:105064. [PMID: 33529836 DOI: 10.1016/j.archoralbio.2021.105064] [Reference Citation Analysis]
82 Li Q, Chen Z. An update: the emerging evidence of complement involvement in COVID-19. Med Microbiol Immunol. 2021;1-9. [PMID: 33811541 DOI: 10.1007/s00430-021-00704-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Chen Y, Chu JMT, Chang RCC, Wong GTC. The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration. Biomolecules 2022;12:337. [PMID: 35204837 DOI: 10.3390/biom12020337] [Reference Citation Analysis]
84 Cardone M, Yano M, Rosenberg AS, Puig M. Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation. Front Immunol 2020;11:1131. [PMID: 32574265 DOI: 10.3389/fimmu.2020.01131] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
85 Zhang S, Zhang J, Wang C, Chen X, Zhao X, Jing H, Liu H, Li Z, Wang L, Shi J. COVID‑19 and ischemic stroke: Mechanisms of hypercoagulability (Review). Int J Mol Med 2021;47:21. [PMID: 33448315 DOI: 10.3892/ijmm.2021.4854] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
86 Kurzawa-Akanbi M, Lotery A, Steel DH, Lako M. Age-related macular degeneration - biomarkers and therapies. Regen Med 2021;16:431-4. [PMID: 34008416 DOI: 10.2217/rme-2021-0059] [Reference Citation Analysis]
87 Hughes S, Gumas J, Lee R, Rumano M, Berger N, Gautam AK, Sfyroera G, Chan AL, Gnanaguru G, Connor KM, Kim BJ, Dunaief JL, Ricklin D, Hajishengallis G, Yancopoulou D, Reis ES, Mastellos DC, Lambris JD. Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Clin Immunol 2020;214:108391. [PMID: 32229292 DOI: 10.1016/j.clim.2020.108391] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
88 Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 2020;16:601-17. [PMID: 33005040 DOI: 10.1038/s41582-020-0400-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
89 Muri L, Ispasanie E, Schubart A, Thorburn C, Zamurovic N, Holbro T, Kammüller M, Pluschke G. Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals. Front Immunol 2021;12:732146. [PMID: 34707606 DOI: 10.3389/fimmu.2021.732146] [Reference Citation Analysis]
90 Mohebnasab M, Eriksson O, Persson B, Sandholm K, Mohlin C, Huber-Lang M, Keating BJ, Ekdahl KN, Nilsson B. Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics. Front Immunol 2019;10:2539. [PMID: 31787968 DOI: 10.3389/fimmu.2019.02539] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
91 Pechlivani N, Kearney KJ, Ajjan RA. Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics. Int J Mol Sci 2021;22:12537. [PMID: 34830419 DOI: 10.3390/ijms222212537] [Reference Citation Analysis]
92 Wenzel UO, Kemper C, Bode M. The role of complement in arterial hypertension and hypertensive end organ damage. Br J Pharmacol 2021;178:2849-62. [PMID: 32585035 DOI: 10.1111/bph.15171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
93 Zhao J, Li Y, Wang Y, Zhang X, Zhang X. Silk sericin-decorated supramolecular photothermal nanocatalyst-based ferric sulfide for boosting high therapeutic performance of tumor cells. Journal of Drug Delivery Science and Technology 2022. [DOI: 10.1016/j.jddst.2022.103104] [Reference Citation Analysis]
94 Teçza M, Kagawa TF, Jain M, Cooney JC. Enzyme kinetic and binding studies identify determinants of specificity for the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease. Comput Struct Biotechnol J 2021;19:2356-65. [PMID: 33897974 DOI: 10.1016/j.csbj.2021.04.024] [Reference Citation Analysis]
95 Ram Kumar Pandian S, Arunachalam S, Deepak V, Kunjiappan S, Sundar K. Targeting complement cascade: an alternative strategy for COVID-19. 3 Biotech 2020;10:479. [PMID: 33088671 DOI: 10.1007/s13205-020-02464-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
96 Friščić J, Böttcher M, Reinwald C, Bruns H, Wirth B, Popp S, Walker KI, Ackermann JA, Chen X, Turner J, Zhu H, Seyler L, Euler M, Kirchner P, Krüger R, Ekici AB, Major T, Aust O, Weidner D, Fischer A, Andes FT, Stanojevic Z, Trajkovic V, Herrmann M, Korb-pap A, Wank I, Hess A, Winter J, Wixler V, Distler J, Steiner G, Kiener HP, Frey B, Kling L, Raza K, Frey S, Kleyer A, Bäuerle T, Hughes TR, Grüneboom A, Steffen U, Krönke G, Croft AP, Filer A, Köhl J, Klein K, Buckley CD, Schett G, Mougiakakos D, Hoffmann MH. The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts. Immunity 2021;54:1002-1021.e10. [DOI: 10.1016/j.immuni.2021.03.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
97 Sultan EY, Rizk DE, Kenawy HI, Hassan R. A small fragment of factor B as a potential inhibitor of complement alternative pathway activity. Immunobiology 2021;226:152106. [PMID: 34147816 DOI: 10.1016/j.imbio.2021.152106] [Reference Citation Analysis]
98 Rushing BR, Rohlik DL, Roy S, Skaff DA, Garcia BL. Targeting the Initiator Protease of the Classical Pathway of Complement Using Fragment-Based Drug Discovery. Molecules 2020;25:E4016. [PMID: 32899120 DOI: 10.3390/molecules25174016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Tabibi S, Tabibi T, Conic RRZ, Banisaeed N, Streiff MB. Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients. J Intensive Care Med 2020;35:827-35. [PMID: 32666875 DOI: 10.1177/0885066620940259] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
100 Michels MAHM, Wijnsma KL, Kurvers RAJ, Westra D, Schreuder MF, van Wijk JAE, Bouts AHM, Gracchi V, Engels FAPT, Keijzer-Veen MG, Dorresteijn EM, Volokhina EB, van den Heuvel LPWJ, van de Kar NCAJ. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort. Pediatr Nephrol 2021. [PMID: 34476601 DOI: 10.1007/s00467-021-05221-6] [Reference Citation Analysis]
101 Jiang H, Chen Q, Zheng S, Guo C, Luo J, Wang H, Zheng X, Weng Z. Association of Complement C3 with Clinical Deterioration Among Hospitalized Patients with COVID-19. IJGM 2022;Volume 15:849-57. [DOI: 10.2147/ijgm.s348519] [Reference Citation Analysis]
102 Lamers C, Mastellos DC, Ricklin D, Lambris JD. Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.01.004] [Reference Citation Analysis]
103 Westacott LJ, Wilkinson LS. Complement Dependent Synaptic Reorganisation During Critical Periods of Brain Development and Risk for Psychiatric Disorder. Front Neurosci 2022;16:840266. [DOI: 10.3389/fnins.2022.840266] [Reference Citation Analysis]
104 Bickel JK, Voisin TB, Tate EW, Bubeck D. How Structures of Complement Complexes Guide Therapeutic Design. Subcell Biochem 2021;96:273-95. [PMID: 33252733 DOI: 10.1007/978-3-030-58971-4_7] [Reference Citation Analysis]
105 Qin S, Dong N, Yang M, Wang J, Feng X, Wang Y. Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. J Immunol Res 2021;2021:9945725. [PMID: 34368372 DOI: 10.1155/2021/9945725] [Reference Citation Analysis]
106 Song L, Ge T, Li Z, Sun J, Li G, Sun Y, Fang L, Ma YJ, Garred P. Artesunate: A natural product-based immunomodulator involved in human complement. Biomed Pharmacother 2021;136:111234. [PMID: 33454596 DOI: 10.1016/j.biopha.2021.111234] [Reference Citation Analysis]
107 Li HY, Tang ZM, Wang Z, Lv JM, Liu XL, Liang YL, Cheng B, Gao N, Ji SR, Wu Y. C-Reactive Protein Protects Against Acetaminophen-Induced Liver Injury by Preventing Complement Overactivation. Cell Mol Gastroenterol Hepatol 2021;13:289-307. [PMID: 34536564 DOI: 10.1016/j.jcmgh.2021.09.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Mastellos DC, Reis ES, Lambris JD. Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads. Front Immunol 2019;10:3029. [PMID: 31998311 DOI: 10.3389/fimmu.2019.03029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
109 Parente R, Doni A, Bottazzi B, Garlanda C, Inforzato A. The complement system in Aspergillus fumigatus infections and its crosstalk with pentraxins. FEBS Lett 2020;594:2480-501. [PMID: 31994174 DOI: 10.1002/1873-3468.13744] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
110 Yarmoska SK, Alawieh AM, Tomlinson S, Hoang KB. Modulation of the Complement System by Neoplastic Disease of the Central Nervous System. Front Immunol 2021;12:689435. [PMID: 34671342 DOI: 10.3389/fimmu.2021.689435] [Reference Citation Analysis]
111 Achazi K, Haag R, Ballauff M, Dernedde J, Kizhakkedathu JN, Maysinger D, Multhaup G. Understanding the Interaction of Polyelectrolyte Architectures with Proteins and Biosystems. Angew Chem Int Ed Engl 2021;60:3882-904. [PMID: 32589355 DOI: 10.1002/anie.202006457] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
112 Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, Tan Y, Wang H, Liu L, Liu Y, Wang G, Yuan Z, Hou X, Ren L, Wu Y, Chen Y. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021;12:2506. [PMID: 33947851 DOI: 10.1038/s41467-021-22781-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
113 Frimat M, Boudhabhay I, Roumenina LT. Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit. Toxins (Basel) 2019;11:E660. [PMID: 31766155 DOI: 10.3390/toxins11110660] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
114 Taylor RP, Lindorfer MA. How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca2. Antibodies (Basel) 2020;9:E45. [PMID: 32899722 DOI: 10.3390/antib9030045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Trzeciak A, Pietropaoli AP, Kim M. Biomarkers and Associated Immune Mechanisms for Early Detection and Therapeutic Management of Sepsis. Immune Netw 2020;20:e23. [PMID: 32655971 DOI: 10.4110/in.2020.20.e23] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
116 Querol LA, Hartung HP, Lewis RA, van Doorn PA, Hammond TR, Atassi N, Alonso-Alonso M, Dalakas MC. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics 2022. [PMID: 35378684 DOI: 10.1007/s13311-022-01221-y] [Reference Citation Analysis]
117 Lim MS, Mcrae S. COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Crit Rev Oncol Hematol 2021;168:103529. [PMID: 34800652 DOI: 10.1016/j.critrevonc.2021.103529] [Reference Citation Analysis]
118 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 King BC, Kulak K, Colineau L, Blom AM. Outside in: Roles of complement in autophagy. Br J Pharmacol 2021;178:2786-801. [PMID: 32621514 DOI: 10.1111/bph.15192] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
120 Roumenina LT, Daugan MV, Petitprez F, Sautès-Fridman C, Fridman WH. Context-dependent roles of complement in cancer. Nat Rev Cancer 2019;19:698-715. [PMID: 31666715 DOI: 10.1038/s41568-019-0210-0] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 22.3] [Reference Citation Analysis]